#USA #Philadelphia #Neurocrine #VYKAT XR #Prader-Willi Syndrome

Research Insights on Prader-Willi Syndrome and VYKAT XR

Neurocrine Biosciences, a leader in biopharmaceuticals, is set to present groundbreaking research focused on Prader-Willi Syndrome (PWS) at the upcoming Foundation for Prader-Willi Research (FPWR) Annual Research Symposium and Family Conference. This event, scheduled for October 7-10, 2026, in Philadelphia, will provide a platform for discussing the advancements in understanding PWS and the real-world applications of VYKAT® XR (diazoxide choline).

Overview of Prader-Willi Syndrome

Prader-Willi syndrome is a complex genetic disorder that significantly impacts individuals and their families. Characterized primarily by hyperphagia—an uncontrollable urge to eat—PWS can lead to severe health issues, including obesity and associated chronic conditions. The condition is caused by abnormalities in chromosome 15 gene expression, with an estimated occurrence of 1 in every 15,000 live births.

Commitment to Research

Neurocrine Biosciences has been at the forefront of addressing the needs of the PWS community. Their FDA-approved treatment, VYKAT XR, is the first of its kind designed specifically for managing hyperphagia in patients aged four and older. At the FPWR symposium, the company aims to share critical findings from ongoing studies, including two primary observational studies:

1. PWS-VISTA: This ongoing study aims to compile long-term real-world evidence on the utility and safety of VYKAT XR in routine clinical settings. Researchers will share demographic and clinical data of patients embarking on treatment with VYKAT XR, contributing to a deeper understanding of its effectiveness and potential outcomes.
2. BRAVE-PWS: Designed with input from caregivers and clinicians, this study focuses on capturing invaluable caregiver-reported insights. It seeks to illuminate the personal experiences and challenges faced by those caring for individuals with PWS, enhancing the understanding of caregiver burdens and needs in the context of this syndrome.

In addition to these observational studies, Neurocrine will present findings related to specific adverse events that may arise during VYKAT XR treatment, such as hyperglycemia and fluid retention, further informing healthcare professionals and caregivers.

Presentations and Insights

Neurocrine is set to deliver several oral and poster presentations at the symposium. Noteworthy sessions include:

• - Real-World Assessment of GLP-1 Receptor Agonist Utilization and Risk of Gastrointestinal Complications in Prader-Willi Syndrome, presented by Dr. Shawn McCandless on October 8.
• - Real-World Demographics and Clinical Characteristics of Patients with Prader-Willi Syndrome Initiating VYKAT XR, presented by Dr. Julie Perry on October 7 as a poster session.
• - Further insights into the burden of caregiving in PWS showcased in the BRAVE-PWS study and comprehensive analyses of adverse effects during VYKAT XR treatment.

The Future of PWS Treatment

Eiry W. Roberts, M.D., Chief Medical Officer of Neurocrine, emphasizes the significance of ongoing research in PWS, stating, "The breadth of research we are presenting at the FPWR Research Symposium reflects our long-term commitment to individuals living with PWS, caregivers, and the broader community. These findings can profoundly inform how we approach treatment and care in this demanding field."

This coming symposium marks a pivotal moment for PWS research and community engagement, providing vital information and support for affected families and healthcare providers. The continuation of these essential studies not only contributes to a more profound understanding of PWS but also affirms Neurocrine’s dedication to advancing treatment options that alleviate the burdens of this challenging condition.

Conclusion

As research unfolds at the FPWR Symposium, the PWS community looks forward to the insights that will emerge, paving the way for enhanced therapeutic strategies and support systems. With VYKAT XR at the forefront of these advancements, Neurocrine Biosciences stands poised to make a significant impact on the lives of individuals affected by Prader-Willi Syndrome.